β-ketoamide compounds with MCH antagonistic activity

US7605176B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Gerald Juergen Roth · Biberach, DE
• Philipp Lustenberger · Warthausen, DE
• Dirk Stenkamp · Biberach, DE
• Stephan Georg Mueller · Warthausen, DE
• Thorsten Lehmann-Lintz · Ochsenhausen, DE
• Marcus Schindler · Schwäbisch Hall, DE
• Leo Thomas · Biberach, DE
• Ralf Lotz · Schemmerhofen, DE
• Marco Santagostino · Magenta, IT

Key dates

• Filing date: Mar 3, 2005
• Grant date: Oct 20, 2009
• Expiry date: Sep 21, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds of formula Iwherein the groups and residues A, B, b, X, Y, Z, R1, R2, R3, R5a and R5b have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.